Insider Transactions in Q1 2024 at Relmada Therapeutics, Inc. (RLMD)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 31
2024
|
Chuck Ence CA and CO |
BUY
Open market or private purchase
|
Direct |
13,670
+25.97%
|
$54,680
$4.05 P/Share
|
|
Jan 31
2024
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
6,875
+16.46%
|
$27,500
$4.06 P/Share
|
|
Jan 31
2024
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
27,460
+10.11%
|
$109,840
$4.0 P/Share
|
|
Jan 30
2024
|
Chuck Ence CA and CO |
BUY
Open market or private purchase
|
Direct |
14,500
+36.43%
|
$43,500
$3.87 P/Share
|
|
Jan 30
2024
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+34.86%
|
$45,000
$3.89 P/Share
|
|
Jan 30
2024
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
40,999
+15.92%
|
$122,997
$3.9 P/Share
|
|
Jan 29
2024
|
Chuck Ence CA and CO |
BUY
Open market or private purchase
|
Direct |
10,800
+50.0%
|
$32,400
$3.65 P/Share
|
|
Jan 29
2024
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,800
+45.32%
|
$32,400
$3.65 P/Share
|
|
Jan 29
2024
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
31,541
+15.23%
|
$94,623
$3.71 P/Share
|